Physician profile
David E Brister
NPI 1568409589
$9,326.81
in general payments reported to CMS, 2019-2025
44 companies · $1,289 in 2025
The $1,289 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,845 · 2020: $990 · 2021: $1,077 · 2022: $1,012 · 2023: $1,790 · 2024: $1,325 · 2025: $1,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,402.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,394.12 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,197.30 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $901.06 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $896.54 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $733.35 | 2019-2025 | Arexvy, Trelegy Ellipta, Rotarix |
| Otsuka America Pharmaceutical, INC. | $467.31 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $429.56 | 2019-2024 | Jardiance |
| Pfizer INC. | $379.10 | 2019-2024 | |
| Astellas Pharma US INC | $336.99 | 2019-2024 | Veozah |
| Amgen INC. | $284.32 | 2019-2024 | Otezla, Repatha |
| Lilly USA, LLC | $262.05 | 2022-2025 | Kisunla, Mounjaro, Zepbound |
| Abbott Laboratories | $187.17 | 2019-2023 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $174.63 | 2024-2025 | Voquezna |
| Eisai INC. | $159.77 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $143.37 | 2019-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.